Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV.

Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13.

PMID:
29248319
2.

Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients.

Hauke RJ Jr, Sissung TM, Figg WD.

Cancer Biol Ther. 2017 Aug 3;18(8):545-546. doi: 10.1080/15384047.2017.1345398. Epub 2017 Jul 5.

3.

Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.

Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI.

Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. doi: 10.1158/1078-0432.CCR-16-2509. Epub 2017 Feb 17.

4.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.

Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S.

Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.

5.

Chemotherapy options in castration-resistant prostate cancer.

Teply BA, Hauke RJ.

Indian J Urol. 2016 Oct-Dec;32(4):262-270. Review.

6.

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.

Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP.

Cancer Immunol Immunother. 2016 Dec;65(12):1533-1544. Epub 2016 Oct 6.

7.

Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.

Milowsky MI, Rumble RB, Booth CM, Gilligan T, Eapen LJ, Hauke RJ, Boumansour P, Lee CT.

J Clin Oncol. 2016 Jun 1;34(16):1945-52. doi: 10.1200/JCO.2015.65.9797. Epub 2016 Mar 21.

PMID:
27001593
8.

Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.

Adra N, Albany C, Brames MJ, Case-Eads S, Johnson CS, Liu Z, Fausel CA, Breen T, Hanna NH, Hauke RJ, Picus J, Einhorn LH.

Support Care Cancer. 2016 Jul;24(7):2837-42. doi: 10.1007/s00520-016-3100-y. Epub 2016 Feb 2.

9.

Sequential Therapy in Metastatic Renal Cell Carcinoma.

Hirsch BR, Burke JM, Agrawal M, Hauke RJ, Hutson TE, Doshi G, Fleming MT, Vogelzang NJ.

J Kidney Cancer VHL. 2016 Apr 5;3(1):23-35. doi: 10.15586/jkcvhl.2016.46. eCollection 2016. Review.

10.

Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement.

Resnick MJ, Lacchetti C, Bergman J, Hauke RJ, Hoffman KE, Kungel TM, Morgans AK, Penson DF.

J Clin Oncol. 2015 Mar 20;33(9):1078-85. doi: 10.1200/JCO.2014.60.2557. Epub 2015 Feb 9.

PMID:
25667275
11.

Immunological basis in the pathogenesis and treatment of bladder cancer.

Thompson DB, Siref LE, Feloney MP, Hauke RJ, Agrawal DK.

Expert Rev Clin Immunol. 2015 Feb;11(2):265-79. doi: 10.1586/1744666X.2015.983082. Epub 2014 Nov 13. Review.

12.

Immunological effects and therapeutic role of C5a in cancer.

Darling VR, Hauke RJ, Tarantolo S, Agrawal DK.

Expert Rev Clin Immunol. 2015 Feb;11(2):255-63. doi: 10.1586/1744666X.2015.983081. Epub 2014 Nov 12. Review.

13.

Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).

Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ.

J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500. Epub 2014 Mar 3.

14.

Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium.

Hauke RJ, Infante JR, Rubin MS, Shih KC, Arrowsmith ER, Hainsworth JD.

Melanoma Res. 2013 Dec;23(6):468-73. doi: 10.1097/CMR.0000000000000014.

PMID:
23969699
15.

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.

Fishman MN, Srinivas S, Hauke RJ, Amato RJ, Esteves B, Cotreau MM, Strahs AL, Slichenmyer WJ, Bhargava P, Kabbinavar FF.

Eur J Cancer. 2013 Sep;49(13):2841-50. doi: 10.1016/j.ejca.2013.04.019. Epub 2013 May 28.

16.

Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: potential role in therapy.

Shimizu T, Torres MP, Chakraborty S, Souchek JJ, Rachagani S, Kaur S, Macha M, Ganti AK, Hauke RJ, Batra SK.

Cancer Lett. 2013 Aug 19;336(2):270-80. doi: 10.1016/j.canlet.2013.03.017. Epub 2013 Mar 21.

17.

Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens.

Hemstreet GP 3rd, Rossi GR, Pisarev VM, Enke CA, Helfner L, Hauke RJ, Tennant L, Ramsey WJ, Vahanian NN, Link CJ.

J Immunother. 2013 Jan;36(1):57-65. doi: 10.1097/CJI.0b013e3182780abc.

PMID:
23211622
18.

Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma--a SEER based study.

Chakraborty S, Hauke RJ, Bonthu N, Tarantolo SR.

Anticancer Res. 2012 Oct;32(10):4507-15.

PMID:
23060579
19.

Incidence and prognostic significance of second primary cancers in renal cell carcinoma.

Chakraborty S, Tarantolo SR, Batra SK, Hauke RJ.

Am J Clin Oncol. 2013 Apr;36(2):132-42. doi: 10.1097/COC.0b013e3182438ddf.

20.

Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with Rituximab.

Chakraborty S, Tarantolo SR, Treves J, Sambol D, Hauke RJ, Batra SK.

Case Rep Oncol. 2011 Jan;4(1):136-42. doi: 10.1159/000326851. Epub 2011 Mar 12.

21.

Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.

Gulec SA, Cohen SJ, Pennington KL, Zuckier LS, Hauke RJ, Horne H, Wegener WA, Teoh N, Gold DV, Sharkey RM, Goldenberg DM.

Clin Cancer Res. 2011 Jun 15;17(12):4091-100. doi: 10.1158/1078-0432.CCR-10-2579. Epub 2011 Apr 28.

22.

Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate.

Elkahwaji JE, Hauke RJ, Brawner CM.

Br J Cancer. 2009 Nov 17;101(10):1740-8. doi: 10.1038/sj.bjc.6605370. Epub 2009 Oct 20.

23.

New onset of heterophilic antibody interference in prostate-specific antigen measurement occurring during the period of post-prostatectomy prostate-specific antigen monitoring.

Fritz BE, Hauke RJ, Stickle DF.

Ann Clin Biochem. 2009 May;46(Pt 3):253-6. doi: 10.1258/acb.2009.008159. Epub 2009 Mar 5.

PMID:
19264827
24.

Novel C5a agonist-based dendritic cell vaccine in a murine model of melanoma.

Floreani AA, Gunselman SJ, Heires AJ, Hauke RJ, Tarantolo S, Jackson JD.

Cell Cycle. 2007 Nov 15;6(22):2835-9. Epub 2007 Aug 15.

PMID:
17986862
25.

Prostate cancer. Clinical practice guidelines in oncology.

Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M 3rd, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Walsh PC; National Comprehensive Cancer Nerwork.

J Natl Compr Canc Netw. 2007 Aug;5(7):650-83. No abstract available.

PMID:
17692170
26.
27.

Kidney cancer. Clinical practice guidelines in oncology.

Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):1072-81. No abstract available.

PMID:
17112454
28.

Testicular cancer. Clinical practice guidelines in oncology.

Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar KS, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):1038-58. No abstract available.

PMID:
17112452
29.

Kidney cancer. Clinical practice guidelines.

Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili R, Pohar KS, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jan;3(1):84-93. No abstract available.

PMID:
19813325
30.

Testicular cancer. Clinical practice guidelines.

Motzer RJ, Bahnson RR, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jan;3(1):52-76. No abstract available.

PMID:
19813323
31.

Treatment of non-Hodgkin lymphoma.

Hauke RJ, Armitage JO.

Curr Opin Oncol. 2000 Sep;12(5):412-8. Review. Erratum in: Curr Opin Oncol 2000 Nov;12(6):598.

PMID:
10975547
32.

A new approach to non-Hodgkin's lymphoma.

Hauke RJ, Armitage JO.

Intern Med. 2000 Mar;39(3):197-208. Review.

33.

Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases.

Hauke RJ, Greiner TC, Smir BN, Vose JM, Tarantolo SR, Bashir RM, Bierman PJ.

Bone Marrow Transplant. 1998 Jun;21(12):1271-4.

34.

Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders.

Smir BN, Hauke RJ, Bierman PJ, Gross TG, d'Amore F, Anderson JR, Greiner TC.

Lab Invest. 1997 Mar;76(3):439. No abstract available.

PMID:
9121126
35.
36.

Central nervous system Hodgkin's disease relapsing with eosinophilic pleocytosis.

Hauke RJ, Tarantolo SR, Bashir RM, Moravec D, Bierman PJ.

Leuk Lymphoma. 1996 Mar;21(1-2):173-5.

PMID:
8907286
37.

Hodgkin's disease following solid organ transplantation.

Bierman PJ, Vose JM, Langnas AN, Rifkin RM, Hauke RJ, Smir BN, Greiner TC.

Ann Oncol. 1996 Mar;7(3):265-70. Review.

PMID:
8740790

Supplemental Content

Loading ...
Support Center